These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 26685859

  • 21. Validation of Hearing Loss Prediction Tool for Cisplatin Chemotherapy and Radiation in Head and Neck Cancer Treatment.
    Deutsch BC, Collopy C, Kallogjeri D, Piccirillo JF.
    JAMA Otolaryngol Head Neck Surg; 2021 Feb 01; 147(2):182-189. PubMed ID: 33300954
    [Abstract] [Full Text] [Related]

  • 22. Risk factors associated with cisplatin-induced ototoxicity in Japanese patients with solid tumors.
    Okada H, Kitagawa K.
    Cancer Med; 2023 Apr 01; 12(7):7904-7910. PubMed ID: 36567514
    [Abstract] [Full Text] [Related]

  • 23. Audiological findings in patients treated with radio- and concomitant chemotherapy for head and neck tumors.
    Dell'Aringa AH, Isaac ML, Arruda GV, Esteves MC, Dell'aringa AR, Júnior JL, Rodrigues AF.
    Radiat Oncol; 2009 Nov 15; 4():53. PubMed ID: 19912669
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Efficacy and tolerability of weekly low-dose cisplatin concurrent with radiotherapy in head and neck cancer patients.
    Otty Z, Skinner MB, Dass J, Collins M, Mooi J, Thuraisingam K, Sabesan S.
    Asia Pac J Clin Oncol; 2011 Sep 15; 7(3):287-92. PubMed ID: 21884441
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-01): A randomized phase II study.
    Driessen CM, de Boer JP, Gelderblom H, Rasch CR, de Jong MA, Verbist BM, Melchers WJ, Tesselaar ME, van der Graaf WT, Kaanders JH, van Herpen CM.
    Eur J Cancer; 2016 Jan 15; 52():77-84. PubMed ID: 26655558
    [Abstract] [Full Text] [Related]

  • 29. Chemoradiation-induced hearing loss remains a major concern for head and neck cancer patients.
    Schmitt NC, Page BR.
    Int J Audiol; 2018 Sep 15; 57(sup4):S49-S54. PubMed ID: 28728452
    [Abstract] [Full Text] [Related]

  • 30. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial.
    Giralt J, Trigo J, Nuyts S, Ozsahin M, Skladowski K, Hatoum G, Daisne JF, Yunes Ancona AC, Cmelak A, Mesía R, Zhang A, Oliner KS, VanderWalde A.
    Lancet Oncol; 2015 Feb 15; 16(2):221-32. PubMed ID: 25596659
    [Abstract] [Full Text] [Related]

  • 31. A randomized controlled trial to test the efficacy of trans-tympanic injections of a sodium thiosulfate gel to prevent cisplatin-induced ototoxicity in patients with head and neck cancer.
    Rolland V, Meyer F, Guitton MJ, Bussières R, Philippon D, Bairati I, Leclerc M, Côté M.
    J Otolaryngol Head Neck Surg; 2019 Jan 16; 48(1):4. PubMed ID: 30651130
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Short-term cohort study on sensorineural hearing changes in head and neck radiotherapy.
    Cheraghi S, Nikoofar P, Fadavi P, Bakhshandeh M, Khoie S, Gharehbagh EJ, Farahani S, Mohebbi A, Vasheghani M, Zare M, Nikoofar A, Mahdavi SR.
    Med Oncol; 2015 Jul 16; 32(7):200. PubMed ID: 26071124
    [Abstract] [Full Text] [Related]

  • 35. Degree of nephrotoxicity after intermediate- or high-dose cisplatin-based chemoradiotherapy in patients with locally advanced head and neck cancer.
    Driessen CM, Uijen MJ, van der Graaf WT, van Opstal CC, Kaanders JH, Nijenhuis T, van Herpen CM.
    Head Neck; 2016 Apr 16; 38 Suppl 1():E1575-81. PubMed ID: 26614010
    [Abstract] [Full Text] [Related]

  • 36. Hearing Loss After Cisplatin-based Chemoradiotherapy for Locally Advanced Head and Neck Cancer: A Prospective Single-institution Study.
    Musio D, DE Vincentiis M, D'Urso P, Musacchio A, Maiuri V, Zaccaro L, Ralli M, Marchetti C, Turchetta R, Tombolini V, DE Felice F.
    Anticancer Res; 2022 Jun 16; 42(6):3003-3009. PubMed ID: 35641273
    [Abstract] [Full Text] [Related]

  • 37. Safety and efficacy of concurrent carboplatin plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin.
    Hamauchi S, Yokota T, Onozawa Y, Ogawa H, Onoe T, Kamijo T, Iida Y, Nishimura T, Onitsuka T, Yasui H.
    Jpn J Clin Oncol; 2015 Dec 16; 45(12):1116-21. PubMed ID: 26423341
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Auditory function and quality of life in patients receiving cisplatin chemotherapy in head and neck cancer: A case series follow-up study.
    Kalyanam B, Sarala N, Azeem Mohiyuddin SM, Diwakar R.
    J Cancer Res Ther; 2018 Dec 16; 14(5):1099-1104. PubMed ID: 30197356
    [Abstract] [Full Text] [Related]

  • 40. Comparison of Patient- and Practitioner-Reported Toxic Effects Associated With Chemoradiotherapy for Head and Neck Cancer.
    Falchook AD, Green R, Knowles ME, Amdur RJ, Mendenhall W, Hayes DN, Grilley-Olson JE, Weiss J, Reeve BB, Mitchell SA, Basch EM, Chera BS.
    JAMA Otolaryngol Head Neck Surg; 2016 Jun 01; 142(6):517-23. PubMed ID: 27149571
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.